HP-501 SR is under clinical development by Hinova Pharmaceuticals and currently in Phase II for Hyperuricemia. According to GlobalData, Phase II drugs for Hyperuricemia have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HP-501 SR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HP-501 SR overview
HP-501 sustained release formulation is under development for the treatment of gout and hyperuricemia. The therapeutic candidate is administered through oral route in the form of sustained release tablet and acts by targeting human uric acid transporter 1 (hURAT1).
It was also under the development for the treatment of chronic kidney disease.
Hinova Pharmaceuticals overview
Hinova Pharmaceuticals (Hinova Pharma) operates as a drug discovery and development company. The Company focuses on the therapeutic areas where there are unmet medical needs. Hinova Pharmaceuticals serves customers globally. Hinova Pharma is headquartered in Chengdu, Sichuan, China.
For a complete picture of HP-501 SR’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
